Dogwood Therapeutics, Inc., headquartered in Alpharetta, Georgia, is a pioneering biotechnology firm dedicated to developing advanced antiviral therapies targeting diseases caused by dysregulated immune responses to viral infections. The company boasts a robust pipeline of innovative therapeutic candidates backed by cutting-edge research, positioning it at the forefront of antiviral treatment innovations. As Dogwood advances through both preclinical and clinical stages, its commitment to improving patient outcomes and addressing significant unmet medical needs places it as a key contender in the rapidly evolving antiviral market. Show more

Location: 44 MILTON AVENUE, ALPHARETTA, GA, UNITED STATES, 30009, Alpharetta, GA, 30009, USA | Website: https://dwtx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

89.51M

52 Wk Range

$2.60 - $15.00

Previous Close

$2.90

Open

$2.86

Volume

52,972

Day Range

$2.75 - $3.04

Enterprise Value

193.5M

Cash

10.13M

Avg Qtr Burn

-3.273M

Insider Ownership

84.27%

Institutional Own.

0.40%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IMC-1 (famciclovir + celecoxib) Details Fibromyalgia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halneuron Details Chemotherapy-induced neuropathic pain	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-2 (valacyclovir and celecoxib) Details Long COVID-19	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SP16 IV (LRP1 Agonist) Details Chemotherapy-Induced Neuropathic Pain	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SP16 IV (LRP1 Agonist) Details Chemotherapy-Induced Neuropathic Pain	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.